Depression (major depressive disorder) clinical trials in Texas
Medical name: Major depressive disorder · Mental health
55 trials are recruiting with sites in Texas, according to ClinicalTrials.gov.
Checked against the registry on 5 October 2026. Listing a trial here is not a recommendation; taking part is voluntary and each study team decides who is eligible.
Study of ALTO-300 in MDD
Ages 18 Years to 70 Years · 38 sites · in Texas: Fort Worth, Plano, Richmond · Alto Neuroscience
Details and how to check if you qualify · NCT05922878 on ClinicalTrials.gov
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Ages 18 Years to 75 Years · 43 sites · in Texas: Austin, Austin, DeSoto, Richardson, Wichita Falls · Draig Therapeutics Ltd
Details and how to check if you qualify · NCT07300969 on ClinicalTrials.gov
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Ages 18 Years to no maximum · 57 sites · in Texas: Bellaire, Stafford, Wichita Falls · Neurocrine Biosciences
Details and how to check if you qualify · NCT07196501 on ClinicalTrials.gov
A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder
Ages 18 Years to 65 Years · 27 sites · in Texas: Dallas · Bristol-Myers Squibb
Pregnenolone Treatment for Alcohol Use Disorder and Major Depressive Disorder
Ages 21 Years to 55 Years · 2 sites · in Texas: Dallas, Richardson · Sherwood Brown, MD, PhD
tDCS for Late-Life Depression
Ages 60 Years to no maximum · 1 site · in Texas: Dallas · Andre Russowsky Brunoni
Pregnenolone for Cannabis Use Disorder and Depression
Ages 18 Years to 50 Years · 2 sites · in Texas: Dallas, Richardson · University of Texas Southwestern Medical Center
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
Ages 18 Years to 75 Years · 169 sites · in Texas: Beaumont, DeSoto, Harlingen, Katy · Eli Lilly and Company
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
Ages 18 Years to no maximum · 26 sites · in Texas: Austin, Dallas, McKinney, Plano · Tonix Pharmaceuticals, Inc.
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
Ages 18 Years to 75 Years · 23 sites · in Texas: DeSoto, Fort Worth · Draig Therapeutics Ltd
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
Ages 18 Years to 74 Years · 30 sites · in Texas: Austin · Definium Therapeutics US, Inc.
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
Ages 18 Years to 74 Years · 45 sites · in Texas: Dallas · Janssen Research & Development, LLC
Using Integrated Care and Wearable Technology to Evaluate Outcomes of the Shields & Stripes Program for Veterans and First Responders
Ages 18 Years to 70 Years · 1 site · in Texas: Waco · Baylor University
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Ages 18 Years to 65 Years · 40 sites · in Texas: Austin, Bellaire, Dallas, Houston, San Antonio · Axsome Therapeutics, Inc.
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Ages 18 Years to 75 Years · 177 sites · in Texas: DeSoto, Fort Worth, Shavano Park · Eli Lilly and Company
Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life Abuse
Ages 21 Years to 70 Years · 1 site · in Texas: Austin · University of Texas at Austin
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
Ages 18 Years to 65 Years · 26 sites · in Texas: DeSoto, Richardson · LB Pharmaceuticals Inc.
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Ages 12 Years to 17 Years · 44 sites · in Texas: Houston · Janssen Research & Development, LLC
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Ages 18 Years to 64 Years · 30 sites · in Texas: Atascocita, Atascocita, DeSoto · Syndeio Biosciences, Inc
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
Ages 18 Years to 65 Years · 33 sites · in Texas: Austin, Austin, Bellaire, Richardson · AbbVie
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Ages 18 Years to 85 Years · 68 sites · in Texas: DeSoto, Houston, San Antonio · Cybin IRL Limited
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Ages 18 Years to 65 Years · 22 sites · in Texas: Houston, Katy, The Woodlands · ACADIA Pharmaceuticals Inc.
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
Ages 18 Years to 66 Years · 40 sites · in Texas: Irving · Seaport Therapeutics
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Ages 18 Years to no maximum · 19 sites · in Texas: Austin · Neurocrine Biosciences
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
Ages 18 Years to 85 Years · 49 sites · in Texas: DeSoto, Houston · Cybin IRL Limited
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Ages 18 Years to 74 Years · 48 sites · in Texas: Austin · Xenon Pharmaceuticals Inc.
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
Ages 22 Years to 75 Years · 3 sites · in Texas: Houston · GrayMatters Health Ltd.
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Ages 18 Years to 65 Years · 56 sites · in Texas: Dallas, Irving, Richardson · Seaport Therapeutics
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Ages 18 Years to no maximum · 97 sites · in Texas: Bellaire, Dallas, DeSoto, Houston, Stafford, The Woodlands · Neurocrine Biosciences
Accelerated Intermittent Theta Burst in Treatment-Naive Adolescents
Ages 13 Years to 20 Years · 1 site · in Texas: Austin · University of Texas at Austin
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Ages 18 Years to no maximum · 34 sites · in Texas: DeSoto · Neurocrine Biosciences
An Open-Label Study of Azetukalner in Major Depressive Disorder
Ages 18 Years to no maximum · 71 sites · in Texas: Austin, Plano, Wichita Falls · Xenon Pharmaceuticals Inc.
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Ages 18 Years to 65 Years · 50 sites · in Texas: Houston, Plano, Richardson, Witchita Falls · Vanda Pharmaceuticals
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Ages 18 Years to 64 Years · 21 sites · in Texas: Austin, DeSoto, Wichita Falls · Syndeio Biosciences, Inc
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Ages 18 Years to no maximum · 13 sites · in Texas: Dallas, Houston · Neurocrine Biosciences
Psilocybin rTMS for Treatment Resistant Depression
Ages 22 Years to 65 Years · 1 site · in Texas: Austin · University of Texas at Austin
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
Ages 18 Years to 65 Years · 48 sites · in Texas: Austin, DeSoto, Plano · atai Therapeutics, Inc.
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Ages 18 Years to 74 Years · 43 sites · in Texas: Plano, Plano, Wichita Falls · Xenon Pharmaceuticals Inc.
Neurobehavioral Therapy For Epilepsy And Major Depressive Disorder
Ages 18 Years to no maximum · 2 sites · in Texas: Houston, Houston · The University of Texas Health Science Center, Houston
ALTO-100 in Bipolar Disorder With Depression (BD-D)
Ages 18 Years to 70 Years · 24 sites · in Texas: Houston · Alto Neuroscience
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Ages 18 Years to 65 Years · 32 sites · in Texas: Beaumont, San Antonio, Sherman · Autobahn Therapeutics, Inc.
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Ages 22 Years to 70 Years · 25 sites · in Texas: Austin, Dallas, Houston, Houston · Abbott Medical Devices
Cortical rTMS as a Treatment for Depression
Ages 18 Years to 64 Years · 1 site · in Texas: Houston · Baylor College of Medicine
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Ages 18 Years to 74 Years · 108 sites · in Texas: Bellaire, Fort Worth, Houston, Wichita Falls · Janssen Research & Development, LLC
Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry
Ages 12 Years to no maximum · 2 sites · in Texas: Plano · Biomedical Discoveries and Neuroscientific Foundations LLC
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Ages 10 Years to 17 Years · 37 sites · in Texas: Austin, Beaumont, Houston, Richmond · Intra-Cellular Therapies, Inc.
Telehealth Behavioral Activation for Teens
Ages 12 Years to 18 Years · 1 site · in Texas: Houston · Baylor College of Medicine
The OBSERVE Protocol
Ages No minimum to no maximum · 6 sites · in Texas: Bellaire · Yale University
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
Ages 21 Years to 45 Years · 2 sites · in Texas: Houston, Houston · Texas A&M University
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
Ages 18 Years to 65 Years · 40 sites · in Texas: Dallas, Dallas, Friendswood, San Antonio, Wichita Falls · Axsome Therapeutics, Inc.
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
Ages 18 Years to 65 Years · 1 site · in Texas: Austin · University of Texas at Austin
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Ages 18 Years to 65 Years · 54 sites · in Texas: Houston, Richardson · Intra-Cellular Therapies, Inc.
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
Ages 18 Years to 40 Years · 6 sites · in Texas: Dallas · Beth Israel Deaconess Medical Center
Triage Survey for Psychiatry Research Eligibility
Ages 18 Years to no maximum · 6 sites · in Texas: DeSoto · Adams Clinical
Integrated Tele-Behavioral Activation and Fall Prevention for Low-income Homebound Seniors With Depression
Ages 50 Years to 100 Years · 1 site · in Texas: Austin · University of Texas at Austin
More: Acne clinical trials · Alzheimer’s disease and related dementias clinical trials · Cannabis use disorder clinical trials · Chronic hives (chronic urticaria) clinical trials · COPD (chronic obstructive pulmonary disease) clinical trials · Moderately to severely active crohn's disease clinical trials
